Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPP-109 (Vigabatrin) in Refractory Tourette's Disorder
NCT01585207Phase 2Completed
- Start
- Jul 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vigabatrin in Tourette syndrome (TS). Primary endpoint: Yale Global Tic Severity Scale Global Severity Score at 10 weeks. Started Jul 2012; status: completed.
02
Drugs
vigabatrin
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT01585207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585207.